Randomized Phase II of Lomustine Versus Lomustine-Dasatinib in Patients With Recurrent Glioblastoma.
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2014
At a glance
- Drugs Dasatinib (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2012 Planned number of patients changed from 108 to 120 as reported by EudraCT.
- 26 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 06 Jul 2011 Planned end date changed from Dec 2011 to May 2011 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History